

## Ascelia Pharma expands its leadership team

Ascelia Pharma AB (publ) (ticker: ACE) a biotech focused on improving the life of people living with rare cancer conditions, today announced that it has expanded its leadership team to include all line functions that report directly to CEO Magnus Corfitzen. The company's Chief Medical Officer (CMO) Carl Bjartmar has decided to retire by the end of 2022.

Ascelia Pharma's new leadership team will consist of the following seven members:

- Magnus Corfitzen, CEO
- Julie Waras Brogren, Deputy CEO & CCO
- Déspina Georgiadou Hedin, CFO
- Andreas Norlin, CSO
- Carin Linde, VP Product Development & Supply and IT
- Marie Källström, VP Regulatory Affairs and QA
- VP Clinical Development (Joins the company in November)

"The expansion of our leadership team is important to prepare for the expected growth ahead of us as we will be moving towards becoming a commercial stage company. I am delighted to announce the promotions of Julie to Deputy CEO, Andreas to CSO and Marie to VP and individually as well as collectively we have a strong leadership team to bring Ascelia Pharma successfully forward," said Magnus Corfitzen, CEO of Ascelia Pharma.

Ascelia Pharma's CMO, Dr Carl Bjartmar has decided to retire by the end of the year.

"I want to thank Carl for his invaluable contributions to Ascelia Pharma over these years and wish him all the best", said Magnus Corfitzen.

### Contacts

---

Magnus Corfitzen, CEO  
Email: [moc@ascelia.com](mailto:moc@ascelia.com)  
Tel: +46 735 179 118

Déspina Georgiadou, CFO and Investor Relations  
Email: [despina.georgiadou@ascelia.com](mailto:despina.georgiadou@ascelia.com)  
Tel: +46 735 17 91 18

*This information was submitted for publication, through the agency of the contact persons set out above.*

## About Us

---

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit <http://www.ascelia.com>.

### **About Orviglance** (previously referred to as Mangoral)

Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

### **About Oncoral**

Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.

## Attachments

---

[Ascelia Pharma expands its leadership team](#)